Follow us on




Q of the week

Q: How Do You Get Shingles?

Get the Answer: 

Prototype devices

It is recognized that a manufacturer may wish to submit a small number  of "prototype models" of a device to clinical investigation in order to assess safety and/or performance; and those such prototypes may need to undergo a number of changes prior to large-scale production.

 Forums
Welcome Guest   [Register]  [Login]
EFGCP–EUCROF Joint Workshop Final Report   by  on 2010-08-20 20:12:20
Managing Clinical Trials   by  on 2010-07-16 00:05:32
US-FDA issues Revised Info Sheet Guidance on Clinical Investigator Disqualification   by  on 2010-06-13 18:11:41
US-FDA issues final guidance on Statement of Investigator (Form FDA 1572)   by  on 2010-06-13 18:07:59
Rising Clinical Trial Complexity Continues to Vex Drug Developers   by  on 2010-06-03 17:36:33
Investigator-Driven Clinical Trials: An ESF Forward Look   by  on 2010-06-03 17:27:58
NIH's Financial Conflict of Interest (FCOI) Proposed Rule   by  on 2010-05-27 19:42:00
AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population   by  on 2010-05-13 19:39:54
Argentina: ANMAT - new regulatory update   by  on 2010-05-01 09:40:32
The Wall Street Journal's special supplement on clinical trials   by  on 2010-05-01 09:31:52
Major developments in EU Clinical Trial Guidances   by  on 2010-04-21 03:10:55
Analysis of the adverse reactions induced by natural product-derived drugs   by  on 2010-04-19 07:16:06
Newer Antibacterial Drugs for a New Century   by  on 2010-04-19 06:49:47
Newer Non-Statin Drugs for Reducing Cholesterol   by  on 2010-04-13 15:57:20
Practice Guidelines for Chronic Pain Management   by  on 2010-04-05 04:52:16
CONSORT III (2010)   by  on 2010-03-29 20:53:28
US FDA Draft Guidance on Pharmacokinetics in Patients with Impaired Renal Function   by  on 2010-03-20 20:25:16
US-FDA issues First Draft Guidance on Noninferiority Trials   by  on 2010-03-04 22:07:46
US FDA new rule on reporting information regarding falsification of data   by  on 2010-02-26 04:47:33
US-FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials   by  on 2010-02-06 20:12:14
 Subject :Plant in Africa's Kalahari Desert holds key to arthritis treatment.. 2009-08-18 17:52:47 
Sushma Naidu
Newbie
Joined: 2009-07-27 17:07:19
Posts: 15
Location

WASHINGTON: Deep in Africa's Kalahari Desert lies the Devil's Claw, a plant that may hold the key to effective treatments for arthritis, tendonitis 
and other illnesses that affect millions each year. In the US, Devil's Claw extracts are in phase-II clinical trials for the treatment of hip and knee arthritis.

Other promising uses are not far behind. Scientists have now successfully reproduced active ingredients in the Devil's Claw. Their technique may eventually lead to the development of "bio-factories" that could produce huge quantities of rare plant extracts quickly and at little cost.

Milen I. Georgiev, a scientist who organises and teaches environment protection, pointed out that for thousands of years, native populations in southern Africa have used the Devil's Claw as a remedy for a huge number of ailments, including fever, diarrhoea and blood diseases.

But while the demand for these beneficial compounds is increasing, the supply of natural Devil's Claw is dwindling, thanks to years of drought, which have pushed the plant towards extinction. Today, there are dozens of medicinal and herbal products around the world that are based on chemicals derived from the plant. "In Germany, 57 pharmaceutical products based on Devil's Claw, marketed by 46 different companies, have cumulative sales volumes alone worth more than $40 million," Georgiev noted. Currently, more than 25 percent of all prescribed medicines used in the industrialised countries are derived either directly or indirectly from plants, many of which are rare and sometimes endangered.

Milen I. Georgiev, a scientist who organises and teaches environment protection, pointed out that for thousands of years, native populations in southern Africa have used the Devil's Claw as a remedy for a huge number of ailments, including fever, diarrhoea and blood diseases. Georgiev notes that hairy roots are a big improvement over traditional, greenhouse-based plant culturing. Georgiev and team are the first to induce hairy root cultures of Devil's Claw.

They took the plant's roots and infected them with the A. rhizogenes soil bacteria - a natural genetic engineer - to create a system of hairy roots to produce the plant's key medicinal chemicals, says a release of the American Chemical Society (ACS).

These findings were reported at the 238th national meeting of the ACS.

 

IP Logged
Page # 


Powered by ccBoard